摘要
目的 观察前列地尔脂微球载体制剂应用于急性冠脉综合征（ACS）的疗效。方法将我院急性冠状动脉综合征患者82例随机分为两组．两组均常规使用冠心病二级预防药物．治疗组于以上治疗基础上加用前列地尔脂微球载体制剂10pg，每日1次．14d为1个疗程．观察两组14d内心绞痛控制情况及1个月内心血管事件发生率．进行比较。结果 对照组缺血性胸痛症状控制总有效率为77，5％．治疗组为92，9％；对照组缺血性胸痛症状控制显效率为40．0％，治疗组为61．9％。治疗组总心血管事件发生率为4．8％．而对照组为22．5％，以上指标．两组比较，差异均有统计学意义（P〈0．05）。结论 前列地尔脂微球载体制剂应用于急性冠脉综合征．效果可靠，无明显不良反应．值得临床推广应用。
Objective To study the efficacy of liposomal prostaglandin E1 on acute coronary syndrome. Methods Eighty-two patients with acute coronary syndrome（ACS） were randomly divided into check group and treatment group, the two groups were treated with conventional coronary heart disease secondary prevention medication,the treatment group was added with liposomal prostaglandin E1 10μg,once daily, the course of treatment was fourteen days,the angina control rate within fourteen days and cardiovascular events rate within one month were compared between two groups. Results The ischemic chest pain control rate within fourteen days and cardiovascular events rate within one month in treatment group was superior to those in check group, there was significant difference between two groups（P〈0.05）. Conclusion Liposomal prostaglandin E1 is effective and safe in the treatment of ACS,it is worthy of expanding in clinical practice.
出处
《中国基层医药》
CAS
2007年第6期913-914,共2页
Chinese Journal of Primary Medicine and Pharmacy
